dr. Flor Verghote (MD)

Research is focused on urothelial cancers, with a primary emphasis on muscle-invasive bladder cancer (MIBC). The main goal is to tailor MIBC treatments to the patient's clinical and personal needs. To achieve this, we investigate the role of radiotherapy across different disease/treatment settings (primary, adjuvant, metastasis-directed). This involves evaluating the impact of modern imaging techniques on initial staging and adjusting treatment accordingly, conducting biomarker research, and performing qualitative research on patient priorities. 
 

• 2021-present: PhD on treatment optimalization for muscle-invasive bladder cancer
• 2020-present: Radiation Oncologist in training – Ghent University Hospital
• 2014-2020: Master of Medicine in Medicine – University of Ghent 
   

• ‘Radical Cystectomy or Trimodality Therapy for Muscle-Invasive Bladder Cancer : A Qualitative Study Exploring Patient Priorities and Counselling Needs When Making a Treatment Choice’. BMC CANCER, 2024. (PMID: 38297192)
• 'Radiotherapy Use in Muscle-Invasive Bladder Cancer: Review of the Guidelines and Impact of Increased Awareness in Patient Referral at a Tertiary Center in Belgium’. CANCER MANAGEMENT AND RESEARCH, 2023. (PMID: 37337479)
• ‘Adjuvant Radiotherapy after Radical Cystectomy for Patients with High-Risk Muscle-Invasive Bladder Cancer : Results of a Multicentric Phase II Trial’. EUROPEAN UROLOGY FOCUS, 2022. (PMID: 34893458)
• ‘International Consensus Guidelines for Adjuvant Radiation Therapy for Bladder Cancer after Radical Cystectomy : Update from an IBIS Workgroup’. PRACTICAL RADIATION ONCOLOGY, 2022. (PMID: 35691550)
• ‘Evaluating the Impact of 18F-FDG-PET-CT on Risk Stratification and Treatment Adaptation for Patients with Muscle-Invasive Bladder Cancer (EFFORT-MIBC) : A Phase II Prospective Trial’. BMC CANCER, 2021. (PMID: 34663254)
   

• Lab Address: Campus UZ Gent, Corneel Heymanslaan 10, 9000 Gent
• LinkedIn
• Flor Verghote is interested to receive invitations for presentations or talks